Noa Schmid
Papers
1
Total Citations
4
H-Index
1
About
Noa Schmid is a researcher whose early work focused on advancing drug development through innovative screening technologies. Her key research area centers on ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) assays, which are critical for evaluating the safety and efficacy of pharmaceutical compounds. Schmid’s major contribution is her pioneering development of three essential ADMET applications—Cytochrome P450 Inhibition, Serum Protein Binding, and P-glycoprotein Interaction—on Tecan’s LabCD-ADMET system. This work, detailed in her 2003 paper (cited 4 times), demonstrated how centrifugal microfluidics could streamline early-stage drug screening, offering a faster, more efficient alternative to traditional methods. While her citation count is modest, the significance of her contribution lies in its practical impact on the drug discovery pipeline, providing a foundation for automated, high-throughput ADME/Tox profiling. Schmid’s research exemplifies the crucial role of assay development in bridging laboratory science and clinical application, making her work a valuable reference for researchers exploring microfluidic platforms in pharmaceutical development.
Research Focus
Key Achievements
Top Papers
- 1ADMET Assays on Tecan's LabCD-ADMET System4 citations · 2003